Olli Huotari SVP, Corporate Functions | Terhi Ormio VP, Communications |
Attached PDF versions:
Orion Annual Report 2010.pdf
Orion Financial Statement documents 2010.pdf
Publisher:
Orion Corporation
Communications
Orionintie 1A, 02200 Espoo
Homepage: www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to approximately EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.